Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7%

Mainz Biomed (NASDAQ:MYNZ) dropped 3.7% during mid-day trading on Friday . The stock traded as low as $0.72 and last traded at $0.74. Approximately 169,563 shares changed hands during mid-day trading, an increase of 66% from the average daily volume of 102,130 shares. The stock had previously closed at $0.77.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MYNZ shares. Cantor Fitzgerald restated a “neutral” rating on shares of Mainz Biomed in a report on Friday, April 12th. HC Wainwright reduced their target price on shares of Mainz Biomed from $5.00 to $3.00 and set a “buy” rating for the company in a report on Wednesday, March 6th.

Mainz Biomed Price Performance

The company has a debt-to-equity ratio of 0.36, a current ratio of 0.97 and a quick ratio of 0.91. The business’s 50-day simple moving average is $0.97 and its 200-day simple moving average is $1.22.

Mainz Biomed (NASDAQ:MYNZ) last posted its earnings results on Tuesday, April 9th. The company reported ($0.24) earnings per share (EPS) for the quarter. Mainz Biomed had a negative net margin of 2,934.82% and a negative return on equity of 488.05%. The firm had revenue of $0.22 million during the quarter. On average, research analysts expect that Mainz Biomed will post -0.88 earnings per share for the current fiscal year.

Mainz Biomed Company Profile

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test.